Erratum to: CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus (Med Oncol (2014), 31, (112), 10.1007/s12032-014-0112-7);CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus

Medical Oncology

Volumn 31, Issue 8, 2014, Pages 1-

  Wang, Juandong ^a   Huang, Tao ^b   Sun, Jianzhi ^b   Yu, Yuan ^b   Liu, Zhifang ^c   Li, Wenjuan ^c   Jia, Jihui ^c   Chen, Chunyan ^b  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Chronic myelocytic leukemia; CIP2A; Proliferation

Indexed keywords

BCR ABL PROTEIN; CANCEROUS INHIBITOR OF PHOSPHATASE 2A; IMATINIB; MESSENGER RNA; MYC PROTEIN; PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN TYROSINE PHOSPHATASE SHP 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AUTOANTIGEN; BENZAMIDE DERIVATIVE; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; K562 CELL LINE; MAJOR CLINICAL STUDY; MALE; ONCOGENE C MYC; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CASE CONTROL STUDY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; APOPTOSIS; AUTOANTIGENS; BENZAMIDES; CASE-CONTROL STUDIES; CELL PROLIFERATION; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MYC; PYRIMIDINES; YOUNG ADULT;

EID: 84905450137     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0211-5     Document Type: Erratum

References (33)

1. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983;306(5940):239-42. (Pubitemid 14232351)
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315(6020):550-4. (Pubitemid 15021190)
3. Lucas C, Wang L, Austin G, Knight K, Watmough S, Shwe K, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22(10):1963-6.
4. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358-63.
5. Barnes DJ, Schultheis B, Adedeji S, Melo JV. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene. 2005;24(42):6432-40. (Pubitemid 41486476)
6. Schultheis B, Szydlo R, Mahon FX, Apperley JF, Melo JV. Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood. 2005;105(12):4893-4. (Pubitemid 40807320)
7. Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, Bulmer SE, et al. The tumor suppressor PP2A Ab regulates the RalA GTPase. Cell. 2007;129(5):969-82. (Pubitemid 46813152)
8. Schönthal AH. Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett. 2001;170(1):1-13. (Pubitemid 32607654)
9. Sontag E. Protein phosphatase 2A: the Trojan Horse of cellular signaling. Cell Signal. 2001;13(1):7-16. (Pubitemid 32222967)
10. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355-65. (Pubitemid 32467045)
11. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8(5):355-68. (Pubitemid 41579831)
12. Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer. 2006;95(7):775-81. (Pubitemid 44500626)
13. Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15(16):5092-100.
14. Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia J, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14(12):3722-8.
15. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130(1):51-62. (Pubitemid 47039258)
16. Yi F, Ni W, Liu W, Bai J, Li W. Expression and biological role of CIP2A in human astrocytoma. Mol Med Rep. 2013;7(5):1376-80.
17. Xu P, Huang Q, Xie F, Xu X-L, Shao F. Increased expression of CIP2A in cholangiocarcinoma and correlation with poor prognosis. Hepatogastroenterology. 2013;60(124):669-72.
18. Laine A. The role of an oncoprotein CIP2A in breast cancer. Turku: University of Turku; 2013.
19. Basile JR, Czerninski R. The role of CIP2A in oral squamous cell carcinoma. Cancer Biol Ther. 2010;10(7):700-2.
20. Qu W, Li W, Wei L, Xing L, Wang X, Yu J. CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol. 2012;29(1):113-8.
21. Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mäder U, et al. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One. 2013;8(10):e75292.
22. Wang L, Gu F, Ma N, Zhang L, Bian J-M, Cao H-Y. CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma. Tumor Biol. 2013:1-5.
23. Shi F, Ding Y, Ju S, Wu X, Cao S. Expression and prognostic significance of CIP2A in cutaneous malignant melanoma. Biomarkers. 2013;19(1):70-6.
24. Böckelman C, Hagström J, Mäkinen L, Keski-Säntti H, Häyry V, Lundin J, et al. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer. 2011;104(12):1890-5.
25. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang Z-P, Cui Q-Z, Wang E-H. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 2011;18(3): 857-65.
26. Ma L, Wen Z-S, Liu Z, Hu Z, Ma J, Chen X-Q, et al. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One. 2011;6(5):e20159.
27. Zhai M, Cong L, Han Y, Tu G. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion. Tumor Biol. 2013;35(2):1123-8.
28. Liu J, Wang X, Zhou G, Wang H, Xiang L, Cheng Y, et al. Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein. Gynecol Oncol. 2011;122(2):430-6.
29. Wang J, Li W, Li L, Yu X, Jia J, Chen C. CIP2A is overexpressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol. 2011;33(3):290-8.
30. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood. 2011;117(24):6660-8.
31. Zhao D, Liu Z, Ding J, Li W, Sun Y, Yu H, et al. Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways. Int J Med Microbiol. 2010;59(3):259-65.
32. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten J-P, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009;101(11):793-805.
33. Liedtke M, Pandey P, Kumar S, Kharbanda S, Kufe D. Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. Oncogene. 1998;17(15):1889.